A Registry-Based Observational Study to Assess Maternal, Pregnancy, and Infant Outcomes Following Exposure to Ixekizumab (I1F-MC-B010) First published 05/11/2021 Last updated 22/04/2024 EU PAS number:EUPAS32751 Study Planned